In this issue:
Lymphoma selection
• Everolimus in WM
• Bortezomib + rituximab in refractory WM
• BEACOPP in refractory/relapsed Hodgkin’s lymphoma
• Methotrexate ± cytarabine in primary CNS lymphoma
• Tumour-associated macrophages and Hodgkin’s lymphoma
prognosis
Leukaemia selection
• NTBI during chemotherapy and conditioning for aSCT
• Allo-SCT for CML in the imatinib era
• Arsenic trioxide in children with APL
• Very long-term APL outcomes
• HBV reactivation after HSCT in anti-HBc-positive patients
Please login below to download this issue (PDF)